Market revenue in 2023 | USD 523.0 million |
Market revenue in 2030 | USD 936.2 million |
Growth rate | 8.7% (CAGR from 2023 to 2030) |
Largest segment | Coronary stents |
Fastest growing segment | Accessory Devices |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Intravascular Imaging Catheters and Pressure Guidewires, Coronary Stents, PTCA Balloon Catheters, Accessory Devices |
Key market players worldwide | Abbott Laboratories, Medtronic PLC, Boston Scientific Corp, Koninklijke Philips NV, Cardinal Health Inc, Terumo Corp, Teleflex Inc, B. Braun, Biosensors, BIOTRONIK, Asahi Intecc Co Ltd, Cook Medical, Merit Medical Systems Inc, Haemonetics Corp, Vascular Solutions, Zeon Corp, Alvimedica, Meril Life, Medinol |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to interventional cardiology devices market will help companies and investors design strategic landscapes.
Coronary stents was the largest segment with a revenue share of 51.05% in 2023. Horizon Databook has segmented the China interventional cardiology devices market based on intravascular imaging catheters and pressure guidewires, coronary stents, ptca balloon catheters, accessory devices covering the revenue growth of each sub-segment from 2018 to 2030.
Factors such as the rising prevalence of CVDs, technological advancements in interventional cardiology devices, and growing investments in healthcare infrastructure are expected to drive the market in the coming years.
According to the Chinese Atherosclerotic Cardiovascular Disease (ASCVD) risk management framework in April 2022, approximately 1.8% of adults are categorized as having a very high risk of CVD, while around 9.4% fall into the high-risk category. This underscores the pressing need for effective intervention and management strategies to address the significant burden of CVDs in China.
The implementation of China's Value-Based Procurement (VBP) program in 2023, which aims to reduce pricing by awarding large volume sales to tender winners, has a significant impact on the interventional cardiology market.
Horizon Databook provides a detailed overview of country-level data and insights on the China interventional cardiology devices market , including forecasts for subscribers. This country databook contains high-level insights into China interventional cardiology devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account